Protocol Ledger

NCT05990192 · Phase II · RECRUITING

SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy

Interventional Phase II clinical trial protocol NCT05990192 sponsored by Institute of Cancer Research, United Kingdom in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-06-20 Enrollment: 42 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05990192
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)42 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05990192
Protocol FieldVerified Registry Value
NCT IdentifierNCT05990192
Consolidated Lead SponsorInstitute of Cancer Research, United Kingdom
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment42 participants (ESTIMATED)
Registered Start Date2024-06-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05990192
Hospital Research SiteLocationSite Profile
Leicester Royal InfirmaryLeicester, United KingdomOpen Hospital Dossier ->
The Christie NHS Foundation TrustManchester, United KingdomOpen Hospital Dossier ->
Western General HospitalEdinburgh, United KingdomOpen Hospital Dossier ->
University College London HospitalsLondon, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI